StockWatch
·

CERA SANITARYWARE LTD. Q2 FY27 Results

CERAQ2 FY27 Results
Filing
Result:Poor· Market: Up#Margin squeeze#Cost led

Outlook: Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue602.9624.1%23.6%
Total Income613.8521.0%21.7%
Expenditure540.8320.9%25.1%
PBT73.0222.1%1.1%
Net Profit56.1423.9%0.9%
OPM12.15%2.02pp1.61pp
NPM9.14%0.21pp2.09pp
EPS43.5223.9%0.9%
View full financials

Core manufacturing metric (adjusted PAT) was flat YoY despite strong revenue growth, as input-cost inflation drove OPM/NPM compression well below management's own margin guidance.

CERA SANITARYWARE · Q2 FY27 · THE VERDICT

The Margin Wall That Revenue Couldn't Climb

CERA posted its strongest topline growth in years — +23.6% YoY — but net profit barely budged. Input cost inflation ate every rupee, and management's margin guidance missed by 130 basis points. The question now is whether H2 price hikes can deliver what Q2 couldn't.

12 Nov 2026 · 6 min read
Revenue

₹603 Cr

+23.6% YoY, +24.1% QoQ

OPM

12.2%

−200 bps YoY, misses 13.5-14% guidance

PAT

₹56.1 Cr

−0.9% YoY flat, +23.9% QoQ

Volume growth

+16.6%

Core retail demand, despite price

The headline reads as a blowout — revenue up ₹23.6% YoY, volumes up 16.6%, faucetware surging +38%, sanitaryware steady at +24%. But scroll to the bottom line: PAT is down 0.9% year-on-year. On ₹603 crore of topline growth, CERA added almost no profit. That is the story of Q2: a company running harder and getting nowhere.

Where the margin went

Operating margin compressed from 14.2% a year ago to 12.2% — a 200 basis point cliff. Management's prior guidance had set a range of 13.5%–14%; the delivered 12.2% represents a miss of 130–250 bps depending on which edge you compare against. Input cost inflation is the culprit. Brass cost up 12% YoY. Gas — at 11–12% of sanitaryware COGS — up 40%. Freight surged 35–50%. Outsourcing partners, who account for 55% of production, carry thin margins and cannot absorb inflation; they pass cost straight to CERA.

Management took pricing action: 12% on sanitaryware in May, another 16% total on faucets by September. But those benefits will not materialize until new orders execute — Q3 and Q4. Q2 captured only a partial lift. As CFO Deepak Chaudhary put it, 'reversals have already been initiated' and the impact will become visible in the second half. That is not a guarantee; it is a road to be walked.

Management's claims vs. what holds up

Revenue growth of 27.4% YoY

Delivered result: 23.6% YoY

Overstated

Strong growth trajectory with volume +16.6%, price +9.1%, mix +1.7%

Supported across all three levers; volumes genuinely strong despite price hikes

Supported

EBITDA margin 13.5–14% for FY27 (guidance from Q1 call)

Q2 delivered 12.2% OPM; FY27 target now revised to 13–14% (lower bound cut 50 bps)

Missed (margin guidance reset downward)

Confident of H2 margin recovery via price realization and cost actions

Price hikes taken, but flow-through in Q3–Q4 unproven; cost actions (automation, in-house shift) ongoing but no concrete $m benefit yet

Partially evidenced, execution risk remains

FY27 revenue growth to surpass 18–20% prior guidance

H1 +23.7%, Q2 +23.6% supports trajectory to exceed 20% for full year

Supported

What changed on this call

Guidance revisions
  • Revenue growth: raised to surpass 18–20% (from target to beat 18–20%)

  • EBITDA margin FY27: cut to 13–14% from 13.5–14%

  • Capex: H1 ₹27 Cr of ₹43 Cr full-year plan; timing under review for greenfield sanitaryware project

  • Project-retail mix: stabilizing toward 40–60% (projects–retail); currently 39–61%

  • FY28 guidance: deferred until end of FY27 (too early given macro uncertainty)

The bull-bear ledger

  • Volume growth +16.6% is real and strong; retail demand is recovering, not just project-driven

  • Sanitaryware and faucetware both growing; portfolio diversification working

  • In-house manufacturing rising (41–55% depending on segment); sourcing advantages vs unorganized competitors

  • Working capital improved: inventory down 14 days YoY, receivables down 5 days; no cash crunch

  • Margin miss is 130–250 bps; needs Q3–Q4 to recover despite size of headwind

  • PAT flat YoY despite 23.6% revenue growth; growth is not translating to earnings

  • Price hike benefits unproven; if demand softens or customers resist, realization lags further

  • Macro uncertainty ('precarious' external environment) capping management's visibility and FY28 guidance

Risks, ranked by how much they should concern a holder

Input cost inflation (brass +12%, gas +40%) persists; limited relief visible

High

Q2 margin 12.2% vs guidance 13.5–14% proves inflation is real and severe. Outsourcing partners (55% of biz) pass costs in full. If inflation sustains, H2 recovery may not reach 13–14% target.

Price hike realization lag; benefits only flow Q3–Q4, not yet proven

High

May +12% and Sept +16% price hikes are in the market, but full benefit requires new orders to execute at higher pricing. If customers order less or project backlogs clear at old pricing, margin benefit undershoots.

Margin guidance miss signals execution risk

Medium

FY27 guidance (13.5–14% margin) set in Q1 call was reset downward (now 13–14%) within one quarter. Forecasting accuracy questioned; if H2 also misses revised target, credibility erodes further.

Macro weakness ('precarious' external environment, geopolitics) could soften demand

Medium

Construction / real estate demand is not assured. Volume growth of +16.6% is strong so far, but discretionary demand in construction could stall if capex softens or interest rates remain elevated.

Project order backlog at old pricing; mix drag until fully transitioned

Low

Older projects deliver at ~39% margin vs newer projects at higher pricing. Until backlog clears, margin recovery will be partial. Not a blocker but a timing headwind.

How the street is positioned

The market has rendered its verdict: bearish. CERA trades at ₹4,893 as of Nov 11, down 54.65% from its all-time high of ₹10,789.95. It sits 15% below its 200-day moving average (₹5,440.67) and 5% below its 50-day average (₹5,146.36), trading above only the 20-day SMA of ₹4,734. RSI of 51.4 signals neutral momentum — the stock is neither oversold nor overbought, just stuck. Volume is normal; there is no capitulation or panic, just steady neglect.

Valuation and drawdown context: A 54.65% drawdown from ATH is severe for a company delivering 23.6% revenue growth and a market-leading position in sanitaryware. Either the market has priced in a permanent margin reset (12% OPM is the new normal), or it is waiting for concrete proof of the H2 recovery before re-rating. The stock's position well below the 200-day MA suggests the latter — skepticism, not capitulation.

Ownership flows: FII ownership ticked up to 15.43% in Q2 (from 14.19% in Q4), a gain of 124 basis points. This is nibbling, not conviction buying — but it signals some value hunters are starting to circle. DII ownership held steady at 14.06% (down 12 bps QoQ from 14.18%), suggesting domestic institutions are not yet adding. Promoter ownership remains locked at 54.41%, providing a steady hand. The bulk/block activity in June 2026 showed Goldman Sachs buying and HDFC Life selling at ₹5,480 — well above current levels — suggesting rotation rather than long-term conviction from large funds at that price.

The market and the fundamentals are aligned on one point: wait and see. Revenue growth is real, but margin recovery is not yet evident. When it is — when Q3 numbers show price hikes flowing through and Q2's 12.2% OPM climbing back toward 13–14% — the re-rating will come. Until then, the stock will trade as a high-growth, low-conviction story.

What to watch next
  • 1 · Q3 margin trajectory

    Does OPM climb from Q2's 12.2% toward the 13–14% target? Price hike benefits should start flowing; watch for evidence in the P&L. If Q3 OPM is still sub-13%, the H2 recovery case weakens materially.

  • 2 · Input cost stabilization

    Brass, gas, and freight inflation are the villain. Any reprieve in commodity prices would help, but management must articulate whether cost pressures are moderating or if pricing will need to hold permanently.

  • 3 · Project order flow and pricing

    Project business is 39–40% of revenue. Watch for visibility on new project awards at higher pricing vs. old backlog burning off at lower pricing. A mix shift toward retail (higher margin, more recurring) or new projects at higher pricing would de-risk the margin story.

CERA remains a steady franchise — dominant market position, real volume growth, and disciplined management. But Q2 represents a step sideways, not forward: the margin compression erased the profit upside of 23.6% revenue growth. Management has a coherent H2 recovery thesis (price flow-through, cost actions, old project backlog clearing), but it is unproven. The market is right to wait.

This is not a collapse or a collapse-in-waiting. It is a quarter where growth did not translate to profit, and the company must now walk the walk. Hold for Q3 results; the number to track from here is operating margin — will it climb from 12.2% or stay pinned? That answer determines whether CERA's re-rating is a Q4 story or a 2027 conversation.

Informational and educational content only. Not investment advice.